SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

Начало・Списък с акции・Fagron

Fagron

Затворен

СекторЗдравеопазване

23.05 1.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.65

Максимум

23.2

Ключови измерители
By Trading Economics
Приходи	-99K 45M
Продажби	-98K 476M
P/E Средно за сектора	17.742 66.418
Дивидентна доходност	1.81
Марж на печалбата	9.55
Служители	4,193
EBITDA	11M 98M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+20.59% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.81% 2.36%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-16M 1.6B
Предишно отваряне	21.95
Предишно затваряне	23.05

Настроения в новините

By Acuity

50%

154 / 348 Класиране в Healthcare

Fagron Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.04.2026 г., 23:25 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13.04.2026 г., 22:45 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13.04.2026 г., 18:03 ч. UTC

Печалби

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13.04.2026 г., 23:58 ч. UTC

Печалби

Review & Preview: Earnings Time -- Barrons.com

13.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13.04.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13.04.2026 г., 21:26 ч. UTC

Значими събития в новините

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13.04.2026 г., 21:16 ч. UTC

Печалби

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13.04.2026 г., 19:59 ч. UTC

Пазарно говорене

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13.04.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13.04.2026 г., 19:27 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Precious Metals Market Talk on April 9

13.04.2026 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13.04.2026 г., 18:43 ч. UTC

Пазарно говорене

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Fagron Прогноза

Ценова цел

By TipRanks

20.59% нагоре

12-месечна прогноза

Среден 19.5 EUR 20.59%

Висок 19.5 EUR

Нисък 19.5 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Fagron през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Fagron през последните 3 месеца.

Настроение

By Acuity

154 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.